<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
ONYX Pharmaceuticals, Inc.
-----------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
-----------------------------------------
(Title of Class of Securities)
683399 10 9
-------------
(CUSIP Number)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 5 Pages
<PAGE> 2
SCHEDULE 13G
CUSIP No. 683399 10 9 Page 2 of 5 Pages
--------------------- ------------------
(1) Names of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Person
Bayer Corporation
25-133-9219
---------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group* (a) [ ]
(b) [ ]
---------------------------------------------------------------------
(3) SEC Use Only
---------------------------------------------------------------------
(4) Citizenship or Place of Organization
Indiana
---------------------------------------------------------------------
(5) Sole Voting Power
Number of 945,510
Shares --------------------------------------------------------
Beneficially (6) Shared Voting Power
Owned by -0-
Each --------------------------------------------------------
Reporting (7) Sole Dispositive Power
Person With 945,510
--------------------------------------------------------
(8) Shared Dispositive Power
-0-
--------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
945,510
---------------------------------------------------------------------
(10) Check box if the Aggregate Amount in Row (9) Excludes Certain
Shares* [ ]
(11) Percent of Class Represented by Amount in Row (9)
9.98%
---------------------------------------------------------------------
(12) Type of Reporting Person*
CO
---------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 5 Pages
<PAGE> 3
ITEM 1(a). NAME OF ISSUER:
ONYX Pharmaceuticals, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
3031 Research Dr.
Richmond, CA 94806
ITEM 2(a). NAME OF PERSON FILING:
Bayer Corporation
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
One Mellon Bank Center, 500 Grant Street, 53rd Floor,
Pittsburgh, Pennsylvania 15219
ITEM 2(c). CITIZENSHIP:
Indiana corporation
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, par value $.001 per share
ITEM 2(e). CUSIP NUMBER:
683399 10 9
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13B-1(b), OR
13d-2(d), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable
ITEM 4. OWNERSHIP:
(a) Amount beneficially owned: 945,510
(b) Percent of Class 9.98%
Page 3 of 5 Pages
<PAGE> 4
(c) Number of Shares as to which such person has:
(i) Sole power to vote or direct the vote: 945,510
(ii) Shared power to vote or direct the vote: -0-
(iii) Sole power to dispose or to direct the
disposition of: 945,510
(iv) Shared power to dispose or to direct the
disposition of: -0-
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON:
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
PARENT HOLDING COMPANY:
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not Applicable
ITEM 10. CERTIFICATION:
Not Applicable
Page 4 of 5 Pages
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of its knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: February 11, 1997 BAYER CORPORATION
By: /s/ JON R. WYNE
--------------------
Jon R. Wyne
Senior Vice President
Page 5 of 5 Pages
